KA Kineta Corp: Net earnings per share for the last 12 months

Kineta Corp (KA) - corporate logo

Kineta, Inc. (KA) is developing advanced immune activation methods to combat resistant tumors. However, the company faces long-term threats from funding shortages and clinical phase uncertainty. Operations within the protected environment of the US guarantee development stability. The YoY TTM EPS growth value visualizes this balance, where the parameter mark equals 80.20, cautioning investors against excessive optimism when analyzing earnings.

KA Kineta Inc Earnings per share for the last twelve months (02/11/2024 - 02/20/2024)
Core merchandise of Kineta Bio

To protect capital amid volatility, tracking real profit dynamics is critical. This indicator captures the percentage change in net income per share over the last twelve months relative to the previous year. Analyzing the annual growth of EPS TTM allows for the identification of business scaling rates. For Kineta, Inc. (KA), this trend reflects the monetization efficiency of its immunological developments. Growth in this metric confirms the potential to secure high royalties from pharmaceutical behemoths.

Competitor analysis for Kineta, Inc.

Earnings per share for the trailing year IBRX (ImmunityBio)|IMCR: Net earnings per share (EPS TTM)|JANX - Net earnings per share for the last four quarters|Earnings per share for the last twelve months arcusbio.com|Net earnings per share for the last 12 months zymeworks.com (ZYME)|Earnings per share for the last twelve months Tango Therapeutics Inc (TNGX)|Net earnings per share for the last 12 months Iovance IOVA|Immatics NV - Net earnings per share for the last 12 months|Net earnings per share (EPS TTM) Xencor Inc. XNCR|CMPX - Earnings per share for the last twelve months|REPL (replimune.com) - Earnings per share for the last 12 months|Lyell Pharma (LYEL) - Earnings per share for the last twelve months|Net earnings per one share for the last twelve months Innate Pharma, S.A. (IPHA)|Net earnings per share for the last 12 months PYXS|CGEN - Net earnings per share for the trailing year|Net earnings per share for the last 12 months IOBT (IO Biotech Corp)|Earnings per share for the last four quarters STRO|Net earnings per share (EPS TTM) INKT (MiNK Therapeutics)|Earnings per share for the trailing year HOWL|Immix - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months ALX Oncology Holdings Inc.|CUE: Net earnings per share (EPS TTM)|PDS Biotech - Earnings per share for the trailing year|SONN (Sonnet BioTherapeutics Holdings Inc.) - Net earnings per share (EPS TTM)|Net earnings per share (EPS TTM) MAIA Biotech|Earnings per share for the last twelve months Liminatus Pharma LLC (LIMN)|LVTX: Earnings per one share for the last 12 months|NextCure Inc - Net earnings per share for the last 12 months|Leap Therapeutics, Inc. (LPTX) - Net earnings per one share for the last twelve months|Intensity Therapeutics Inc - Net earnings per share (EPS TTM)|Net earnings per share for the last four quarters senseibio.com SNSE|TOVX: Net earnings per share (EPS TTM)|Gritstone bio Inc. - Earnings per share for the trailing year|Net earnings per share for the last 12 months NEXI|TSBX: Earnings per share for the trailing year|Net earnings per share (EPS TTM) VCNX|HARP: Earnings per one share for the last 12 months